multiple system atrophy

multiple system atrophy
Jensflorian · CC BY-SA 3.0 · source
Name	Multiple system atrophy
Specialty	Neurology

multiple system atrophy is a progressive neurodegenerative disorder characterized by combined autonomic failure, parkinsonism, and cerebellar ataxia. It affects motor control, cardiovascular regulation, and gait, producing symptoms that overlap with Parkinson disease, cerebellar degeneration, and autonomic neuropathies. Presentation, course, and response to therapy vary, complicating diagnosis and management.

Signs and symptoms

Patients develop autonomic failure with orthostatic hypotension, urinary incontinence, and erectile dysfunction alongside parkinsonian features such as bradykinesia, rigidity, and postural instability. Cerebellar signs can include ataxia, dysarthria, and limb coordination problems, often leading to falls and dysphagia. Additional features may include sleep disturbances such as REM sleep behavior disorder, respiratory stridor, and cognitive changes that may be mistaken for dementia syndromes. Clinical overlap leads to misdiagnosis with James Parkinson-associated paradigms, referral patterns involving institutions like Mayo Clinic and Johns Hopkins Hospital, and engagement with advocacy groups such as Michael J. Fox Foundation for Parkinson's Research and Parkinson's Foundation.

Pathology and causes

Pathologically, multiple system atrophy is defined by glial cytoplasmic inclusions composed primarily of alpha-synuclein aggregates in oligodendrocytes, together with neuronal loss in the striatonigral and olivopontocerebellar systems. Molecular studies implicate alpha-synuclein misprocessing and propagation pathways studied by researchers at Columbia University and University College London, with genetic and environmental modifiers under investigation in cohorts from Harvard Medical School and Karolinska Institutet. Neuropathological staging links involvement of the substantia nigra, putamen, pons, cerebellum, and autonomic nuclei, paralleling descriptions from archives at National Institutes of Health and neuropathology centers like MRC London Neurodegeneration Biobank. Proposed etiologies include sporadic proteinopathy, mitochondrial dysfunction, oxidative stress, and neuroinflammation, with mechanistic work from laboratories affiliated with Massachusetts Institute of Technology, Stanford University, and Max Planck Society.

Diagnosis

Diagnosis relies on clinical criteria integrating autonomic failure with either parkinsonism or cerebellar signs and is supported by neuroimaging and autonomic testing. Brain MRI may show putaminal atrophy, pontine "hot cross bun" sign, and cerebellar degeneration noted in radiology units at Mayo Clinic Arizona and Mount Sinai Hospital. Functional imaging such as dopamine transporter SPECT and PET scans conducted at centers like UCLA and Yale University can help differentiate from Parkinson disease and progressive supranuclear palsy. Autonomic testing (tilt-table, urodynamics) and polysomnography are performed in sleep labs affiliated with Kings College Hospital and Cleveland Clinic. Differential diagnosis commonly involves consultation with specialists at Addenbrooke's Hospital, Toronto Western Hospital, and referral networks including European Academy of Neurology and American Academy of Neurology.

Treatment and management

No disease-modifying therapy is approved; management is symptomatic and multidisciplinary, involving neurologists, cardiologists, urologists, physiotherapists, and speech therapists. Levodopa may offer transient benefit for parkinsonism in some patients treated in movement disorder clinics such as Imperial College Healthcare NHS Trust and Duke University Hospital, while autonomic symptoms are managed with volume expansion, fludrocortisone, midodrine, and nonpharmacologic measures taught in clinics at Royal College of Physicians. Management of bladder dysfunction employs intermittent catheterization, botulinum toxin injection performed in urology centers like Mayo Clinic Rochester and Johns Hopkins Medicine, and pelvic floor rehabilitation programs at UCSF Medical Center. Advanced care requires palliative input from teams associated with St Christopher's Hospice and Hospice UK, and respiratory complications may necessitate tracheostomy or CPAP at respiratory centers such as Guy's and St Thomas' NHS Foundation Trust.

Prognosis and epidemiology

Multiple system atrophy typically progresses more rapidly than Parkinson disease, with median survival around 6–10 years from symptom onset in cohort studies from Oslo University Hospital and Charité – Universitätsmedizin Berlin. Incidence estimates vary by region; population-based studies from Japan, Sweden, and Australia report low prevalence consistent with a rare disease designation, while registry efforts coordinated through organizations like European MSA Study Group and North American Autonomic Disorders Consortium track epidemiologic trends. Prognostic factors include early autonomic failure, rapid motor progression, respiratory involvement, and older age at onset. Socioeconomic and healthcare access disparities influence outcomes in systems such as National Health Service (England) and Medicare (United States).

Research directions and experimental therapies

Ongoing research targets alpha-synuclein aggregation, oligodendroglial pathology, and neuroinflammation, with preclinical and clinical studies led by institutions including Biogen, Roche, Novartis, and academic groups at University of Oxford and University of Cambridge. Gene-expression profiling, proteomics, and biomarker discovery are pursued at Broad Institute and European Molecular Biology Laboratory, while immunotherapy, small-molecule aggregation inhibitors, antisense oligonucleotides, and cell-replacement approaches are evaluated in trials registered through networks coordinated by World Health Organization and ClinicalTrials.gov. Stem cell research in centers like Karolinska University Hospital and neuroprotective strategies explored at Scripps Research aim to modify disease trajectory. Collaborative consortia such as Consortium of European MSA Researchers and industry partnerships sponsor phase I–III trials, and adaptive trial designs advocated by US Food and Drug Administration and European Medicines Agency are shaping future therapeutic development.

Category:Neurodegenerative diseases